{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:27:18Z","timestamp":1794432438068,"version":"4.9.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["GZ-2015-11336"],"award-info":[{"award-number":["GZ-2015-11336"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pompe disease, a lysosomal storage disorder, is characterized by acid \u03b1-glucosidase (GAA) deficiency and categorized into two main subtypes: infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD). The primary treatment, enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA), faces challenges due to immunogenic responses, including the production of anti-drug antibody (ADA), which can diminish therapeutic efficacy. This study aims to assess the effectiveness of immune tolerance induction (ITI) therapy in cross-reactive immunologic material (CRIM)-positive Pompe disease patients with established high ADA levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In a single-center, open-label prospective study, we assessed ITI therapy\u2019s efficacy in Pompe disease patients, both IOPD and LOPD, with persistently elevated ADA titers (\u22651:12,800) and clinical decline. The ITI regimen comprised bortezomib, rituximab, methotrexate, and intravenous immunoglobulin. Biochemical data, biomarkers, ADA titers, immune status, and respiratory and motor function were monitored over six months before and after ITI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study enrolled eight patients (5 IOPD and 3 LOPD). After a 6-month ITI course, median ADA titers significantly decreased from 1:12,800 (range 1:12,800-1:51,200) to 1:1,600 (range 1:400-1:12,800), with sustained immune tolerance persisting up to 4.5 years in some cases. Serum CK levels were mostly stable or decreased, stable urinary glucose tetrasaccharide levels were maintained in four patients, and no notable deterioration in respiratory or ambulatory status was noted. Adverse events included two treatable infection episodes and transient symptoms like numbness and diarrhea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      ITI therapy effectively reduces ADA levels in CRIM-positive Pompe disease patients with established high ADA titers, underscoring the importance of ADA monitoring and timely ITI initiation. The findings advocate for personalized immunogenicity risk assessments to enhance clinical outcomes. In some cases, prolonged immune suppression may be necessary, highlighting the need for further studies to optimize ITI strategies for Pompe disease treatment. ClinicalTrials.gov NCT02525172;\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT02525172<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1336599","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:27:01Z","timestamp":1713832021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Hui-An","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rai-Hseng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ya","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit K.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuu-Jen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-011-9404-7","article-title":"Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy","volume":"35","author":"van Gelder","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301912","article-title":"Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease","volume":"14","author":"Desai","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100475","DOI":"10.1016\/j.ymgmr.2019.100475","article-title":"Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86821","article-title":"Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses","volume":"1","author":"Kazi","year":"2016","journal-title":"JCI Insight"},{"key":"B13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13023-019-1039-z","article-title":"Effects of immunomodulation in classic infantile Pompe patients with high antibody titers","volume":"14","author":"Poelman","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21037\/atm","article-title":"Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review","volume":"7","author":"Desai","year":"2019","journal-title":"Ann Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.14070","article-title":"Infantile-onset Pompe disease: A case series highlighting early clinical features, spectrum of disease severity and treatment response","volume":"54","author":"Owens","year":"2018","journal-title":"J Paediatr Child Health"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.05.006","article-title":"High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol Genet Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"36182","DOI":"10.1038\/srep36182","article-title":"Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients","volume":"6","author":"Masat","year":"2016","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nmd.2022.01.001","article-title":"Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease","volume":"32","author":"Winkler","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0270-7","article-title":"An immune tolerance approach using transient low-dose methotrexate in the ERT-naive setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease","volume":"21","author":"Kazi","year":"2019","journal-title":"Genet Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100893","DOI":"10.1016\/j.ymgmr.2022.100893","article-title":"A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation","volume":"32","author":"Curelaru","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/1363849031000139298","article-title":"Development of a disease-specific disability instrument for Pompe disease","volume":"6","author":"Haley","year":"2003","journal-title":"Pediatr Rehabil"},{"key":"B26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/ijns6020030","article-title":"The timely needs for infantile onset pompe disease newborn screening-practice in Taiwan","volume":"6","author":"Chiang","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00926-5","article-title":"Assessing the role of anti rh-GAA in modulating response to ERT in a late-onset pompe disease cohort from the italian GSDII study group","volume":"36","author":"Filosto","year":"2019","journal-title":"Adv Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2019.07.013","article-title":"Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT","volume":"128","author":"Fernandez-Simon","year":"2019","journal-title":"Mol Genet Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100981","DOI":"10.1016\/j.ymgmr.2023.100981","article-title":"Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy","volume":"36","author":"Kim","year":"2023","journal-title":"Mol Genet Metab Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05672-5","article-title":"Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease","volume":"38","author":"Sasaki","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31320","article-title":"Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques","author":"Young","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1336599\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:27:03Z","timestamp":1713832023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1336599\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2024.1336599"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1336599","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"article-number":"1336599"}}